Home
About Us
Core Team
Development History
Corporate Culture
S&T
Research Areas
Technology Platforms
Research and Development
Marketed Products
R&D Products
R&D Pipeline
Academic Progress
Blog
Company News
Media Reports
Join Us
Post-Doctoral Center
Contact Us
[Case Study] Issue 278: Nilotinib Treatment for Recurrent Cholangiocarcinoma
View details
→
[XinSheng Academic] A prospective Phase II study of EGFR monoclonal antibody combined with concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma resistant to induction chemotherapy demonstrates significant efficacy of nimotuzumab.
【XinSheng Academic】Interim analysis of the Phase III clinical trial evaluating nimotuzumab in combination with concurrent chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma (ESCC) officially published
[Case Study] Issue 277: Nilotinib Treatment for Diffuse Midline Glioma
[Case Study] Issue 276: Nilotinib Treatment for Nasopharyngeal Cancer Complicated by Paraneoplastic Syndrome
[Case Study] Issue 275: Nilotinib for Diffuse Midline Glioma